Cogent Biosciences Q2 FY26 net loss widens to $96.4 million; R&D expenses rise to $70.8 million

Reuters2026/08/10 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cogent Biosciences posted a GAAP net loss of USD 96.4 million for Q2 2026, widening from USD 73.5 million a year earlier.
R&D expense rose 13.83% to USD 70.8 million, driven by SUMMIT, PEAK and APEX trial costs, regulatory work and pipeline investment.
G&A expense more than doubled to USD 31.8 million, on higher commercial readiness spending tied to a potential bezuclastinib launch.
Cash, cash equivalents and marketable securities totaled USD 792.3 million at June 30; pro forma cash was USD 865.9 million, funding operations into late 2028.
FDA accepted an NDA with priority review for bezuclastinib in GIST, with a PDUFA date of Nov. 30, 2026; an AdvSM NDA was submitted June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800PRIMZONEFULLFEED9806537) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cogent Biosciences Q2 FY26 net loss widens to $96.4 million; R&D expenses rise to $70.8 million

You may also like

Crypto prices